Skip to main content
Category

Insights

Solving an Unmet Need: A New Diagnostic Paradigm for Neurodegenerative Disorders

By Insights

Arriving at a definitive diagnosis of any given neurodegenerative condition is not always easy. Recent studies have shown that even in the hands of the best movement disorder specialists, patients diagnosed
with Parkinson’s disease who come to autopsy show no evidence of Lewy bodies and have an alternate diagnosis 30% of the time. Similar data exist for patients with multiple sclerosis, Alzheimer’s disease, and immune-mediated neuropathies. These data tell us that clinical diagnostic skills and tests cannot always accurately distinguish the varied forms of neurodegenerative diseases.

Read More

Researchers Detect Alpha-Synuclein in Nerve Biopsy 6 Years Before Clinical Diagnosis of Dementia With Lewy Bodies

By Insights

Dr. Todd Levine, CND Life Sciences’ Co-Founder and CMO, will speak at the product presentation theater at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting this month. His talk, “In-Office Cutaneous Testing for Pure Autonomic Failure and Other Synucleinopathies: Introducing the Syn-One Test™,” will be held Friday, October 15 at 3:40 pm MST.

Read More

CND Life Sciences’ Chief Medical Officer to Present at AANEM Annual Meeting

By Insights

Dr. Todd Levine, CND Life Sciences’ Co-Founder and CMO, will speak at the product presentation theater at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting this month. His talk, “In-Office Cutaneous Testing for Pure Autonomic Failure and Other Synucleinopathies: Introducing the Syn-One Test™,” will be held Friday, October 15 at 3:40 pm MST.

Read More